Most people assume that losing muscle as a liver condition progresses is just part of getting sicker, the body shutting down in a uniform, predictable way. But that assumption turns out to be wrong in ways that matter enormously for treatment. The muscles of someone with alcohol-related cirrhosis are breaking down through a completely different chain of events than the muscles of someone with fatty liver disease, and that distinction changes everything about what can actually be done to help them.
The field of hepatology (the study of liver disease) has long recognized that skeletal muscle loss is one of the most serious complications a liver patient can face. What it has been slower to accept is that “muscle loss in liver disease” is not a single problem. It is several distinct problems that share the same outward appearance but have very different roots. Recent research is finally mapping those roots, and the picture it is painting has real consequences for patients and their doctors.
Understanding which type of liver disease is driving liver disease muscle loss, and why, is the difference between targeted intervention and treating the wrong problem entirely. Here is what the evidence now shows about how four major liver conditions each attack muscle in their own way.
1. Liver Cirrhosis: When Your Muscles Work Overtime for a Failing Liver
Sarcopenia, the loss of skeletal muscle mass and strength, affects a significant proportion of people who develop end-stage liver disease. The overall prevalence of sarcopenia in patients with cirrhosis is around 40%, according to a systematic review and meta-analysis published in a 2023 peer-reviewed journal. In cirrhosis, the liver has been so severely scarred that it can no longer perform many of its core functions. The resulting crisis does not stay in the liver. The body calls on skeletal muscle to fill the gaps, and this relentless demand eventually destroys it.
The key driver of this process is ammonia. Hyperammonemia – meaning abnormally high ammonia levels in the blood – is a consistent abnormality in cirrhosis, caused by impaired conversion of ammonia to urea in the liver. Urea genesis is the process by which the liver normally converts toxic ammonia into a harmless compound that gets flushed out in urine. When the liver can no longer do this job, skeletal muscle steps in to absorb the excess ammonia. This works in the short term, but it comes at a steep price.
Raised skeletal muscle myostatin expression, reduced mTORC1 function, and the hyperammonemic stress response – including activation of autophagy pathways – are all consequences of excess ammonia in the muscle, as demonstrated in preclinical research. MtORC1 is the molecular switch that drives new muscle protein production; when it is suppressed, muscle construction slows. Research published in PNAS showed that myostatin, a known inhibitor of skeletal muscle growth, is increased in the cirrhotic muscle, driven by the activation of a transcription factor called NF-κB in response to elevated ammonia concentrations. The result is a double blow: muscle construction slows, and muscle breakdown accelerates.
The pathogenesis of sarcopenia in cirrhosis is multifactorial, involving an imbalance between protein synthesis and breakdown, with nutritional, metabolic, and biochemical abnormalities all altering whole-body protein homeostasis. Hyperammonemia, increased autophagy, proteasomal activity, lower protein synthesis, and impaired mitochondrial function each play a role.
Sarcopenia is present in 30 to 70% of cirrhosis patients and is associated with poor prognosis due to related complications including hepatic encephalopathy, ascites, and portal hypertension. The practical takeaway for anyone managing a cirrhosis patient is that nutrition and protein intake cannot be treated as secondary concerns. Ammonia-lowering strategies, such as targeted dietary protein protocols and specific gut-based interventions, directly affect how fast muscle deteriorates.
2. Alcohol-Associated Liver Disease: The Fastest Route to Muscle Loss
Alcohol-associated liver disease (ALD) is not just cirrhosis caused by a different trigger. The presence of alcohol itself adds a separate layer of direct muscle toxicity that makes this condition the most damaging of all liver diseases when it comes to skeletal muscle.
Alcoholic liver disease has been associated with a high prevalence of sarcopenia, affecting around 80% of patients with decompensated cirrhosis, according to observational data published in a peer-reviewed hepatology journal. That gap compared to other forms of cirrhosis is not explained by liver severity alone. Both direct effects of ethanol (the alcohol in alcoholic beverages) and its metabolites on skeletal muscle and the consequences of liver disease result in disturbed proteostasis – the process of maintaining normal protein balance – and consequent sarcopenia.
Ethanol reduces muscle protein synthesis and accelerates proteolysis – the breakdown of protein into its component amino acids. Alcohol and its primary breakdown product, acetaldehyde, interfere with how muscle cells function at the cellular level, independent of what is happening in the liver at the same time.
The speed of decline sets ALD apart in measurable terms. A 2024 study published in the Journal of Gastroenterology found that patients with ALD cirrhosis experienced more rapid annual muscle loss (5.7%) than those with hepatitis B cirrhosis (2.8%) or hepatitis C cirrhosis (3.1%). Nearly double the rate of viral hepatitis. Over a median follow-up of 3.8 years, ALD cirrhosis, rapid muscle loss, and low subcutaneous fat levels were all significantly associated with reduced survival, with ALD cirrhosis independently predictive of mortality. This is why the clinical picture for ALD patients deteriorates so quickly, and why waiting to intervene is so costly. For patients with ALD, alcohol cessation is not only a liver treatment. It is a muscle treatment.
3. MASLD (Metabolic Fatty Liver Disease): Muscle and Liver Destroying Each Other
MASLD, short for metabolic dysfunction-associated steatotic liver disease, is what most people would formerly have known as non-alcoholic fatty liver disease (NAFLD). It is the most common form of chronic liver disease worldwide, driven by the intersection of excess body fat, insulin resistance (the body’s failure to respond normally to the hormone insulin), and metabolic dysfunction.
The bidirectional relationship between MASLD and sarcopenia is supported by shared mechanisms including insulin resistance, chronic inflammation, and altered protein metabolism. What makes MASLD distinct from other liver diseases is that the liver and the muscle are each making the other worse, in a self-reinforcing cycle. Sarcopenia has been found to be significantly associated with MASLD patients across multiple studies, with findings consistent across subgroups stratified by age, study design, and methods for measuring muscle mass.
The mechanics work like this: insulin resistance in skeletal muscle reduces the muscle’s ability to take up glucose, so blood sugar stays elevated, which stresses the liver further. A weaker, less metabolically active muscle produces fewer of the beneficial signaling molecules called myokines that normally protect the liver from inflammation. The liver, meanwhile, generates more inflammatory signals that further impair muscle function. It is a loop with no obvious entry point to break it.
The numbers from population research are striking. A 2026 systematic review and meta-analysis published in Frontiers in Nutrition, drawing on data from over 100,000 patients across 21 studies, found that sarcopenia was associated with a 1.58-fold increased risk of NAFLD and a 2.03-fold increased risk of liver fibrosis in patients with NAFLD. Having less muscle makes fatty liver worse, and fatty liver makes it harder to maintain muscle. The association between sarcopenia and all-cause mortality in MASLD patients further supports the link between muscle decline and poor prognosis, with sarcopenia strongly correlated with MASLD progression and mortality risk. The risk persists even among people whose weight and blood sugar levels appear controlled, which makes regular muscle assessment particularly important in this group.
For people with MASLD, building and preserving lean muscle mass is not just a fitness goal. It is a direct strategy to slow liver disease. Resistance training and adequate dietary protein become medical interventions, not lifestyle add-ons. You can read more about how fatty liver disease progresses and the steps that can interrupt that process.
4. Cirrhosis-Driven Hepatic Encephalopathy: When Liver Disease Muscle Loss Changes the Brain
This fourth pattern is closely connected to advanced cirrhosis, but it deserves its own discussion because the muscle-brain relationship is distinct, measurable, and often overlooked until damage is already extensive.
Hepatic encephalopathy (HE) refers to a decline in brain function that occurs when a damaged liver can no longer filter toxins, particularly ammonia, from the blood. Ammonia crosses the blood-brain barrier and disrupts normal neurological function, causing confusion, disorientation, and in severe cases, coma. What fewer people appreciate is how dramatically muscle mass determines whether a person with cirrhosis develops this complication.
In cirrhotic patients, sarcopenia contributes to hyperammonemia because sarcopenic muscle has a reduced capacity to detoxify circulating ammonia, which increases the risk of hepatic encephalopathy. Hyperammonemia then further worsens muscle depletion through myostatin upregulation, mitochondrial dysfunction, and cellular stress, creating a vicious cycle. The less muscle a person has, the faster ammonia accumulates, and the more vulnerable their brain becomes.
A large meta-analysis of 22 studies involving nearly 7,000 cirrhosis patients found that sarcopenia was associated with more than a two-fold increased risk of mortality, with consistent findings across subgroups stratified by sex, liver disease cause, and severity of liver dysfunction. A patient who arrives with significant muscle loss at a hepatology clinic is not just malnourished. They are at measurably higher risk for a brain crisis that could be the event that ends their chance at liver transplantation. Clinicians who screen only for liver function markers and overlook muscle mass are missing one of the most important predictors of what happens next.
Research tracking body composition in cirrhosis patients over time found that the greatest rate of muscle loss was observed in patients with ALD, with the etiology (cause of the disease) of liver disease identified as an independent risk factor for sarcopenia. On that note, the popular practice of supplementing with branched-chain amino acids has been challenged by recent trial data. While randomized controlled data have supported BCAA use in cirrhosis for managing hepatic encephalopathy symptoms and low albumin, results from randomized controlled trials examining BCAAs specifically as a therapy for sarcopenia have been conflicting. Patients and clinicians should discuss with their care team whether supplementation is matched to the specific mechanism driving muscle loss in their case, rather than applying a one-size-fits-all approach.
Read More: 9 Foods That Support Liver Function
What This Means for You
The research now makes a compelling case that liver disease muscle loss is not one condition wearing different masks. The biological pathways responsible for muscle wasting in MASLD are driven by metabolic dysfunction and fat infiltration. In cirrhosis and alcohol-associated liver disease, the triggers are ammonia toxicity, direct ethanol damage, and dysregulated protein metabolism. And in advanced cirrhosis, the muscle-brain feedback loop creates complications that go far beyond the liver itself. Each disease writes a different story in the muscle, and reading that story correctly changes how treatment should be approached.
That distinction matters practically. If you or someone you care for is living with a chronic liver condition, the most useful question to bring to a hepatologist is not simply “how is my liver doing?” but also “how is my muscle doing, and what is the most likely reason it is being affected?” Researchers suggest that MASLD patients should undergo routine sarcopenia screening, and that interventions targeting muscle health may benefit both the muscle and the liver simultaneously. The same logic applies across liver disease types. Muscle preservation is not a secondary concern or a rehabilitation afterthought. For people with liver disease, it is a core part of staying well – and staying alive.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: This Common Dry Cleaning Chemical May Be Tripling Your Liver Disease Risk